Title: Identification of secretaglobin Scgb2a1 as a target for developmental reprogramming by BPA in the rat prostate.
Authors: Wong, Rebecca Lee Yean; Wang, Quan; Treviño, Lindsey S; Bosland, Maarten C; Chen, Jing; Medvedovic, Mario; Prins, Gail S; Kannan, Kurunthachalam; Ho, Shuk-Mei; Walker, Cheryl Lyn
Published In Epigenetics, (2015)
Abstract: Secretoglobins are a superfamily of secreted proteins thought to participate in inflammation, tissue repair, and tumorigenesis. Secretoglobin family 2A member 1 (Scgb2a1) is a component of prostatein, a major androgen-binding protein secreted by the rat prostate. Using a rat model for developmental reprogramming of susceptibility to prostate carcinogenesis, we identified, by RNA-seq, that Scgb2a1 is significantly upregulated (>100-fold) in the prostate of adult rats neonatally exposed to bisphenol A (BPA), with increased gene expression confirmed by quantitative RT-PCR and chromatin immunoprecipitation for histone H3 lysine 9 acetylation. Bisulfite analysis of both CpG islands located within 10 kb of the Scgb2a1 promoter identified significant hypomethylation of the CpG island upstream of the transcription start site of this gene in the reprogrammed prostate. These data suggest that expression of Scgb2a1 in the adult prostate could be epigenetically reprogrammed by BPA exposure during prostate development, with potential implications for cancer risk and response to chemotherapeutics associated with prostatein binding.
PubMed ID: 25612011
MeSH Terms: Acetylation; Animals; Animals, Newborn; Benzhydryl Compounds/toxicity*; Cellular Reprogramming/drug effects*; CpG Islands/drug effects; DNA Methylation/drug effects; Estrogens, Non-Steroidal/toxicity*; Histones/metabolism; Lysine/metabolism; Male; Mammaglobin B/metabolism*; Phenols/toxicity*; Promoter Regions, Genetic/drug effects; Prostate/drug effects*; Prostate/growth & development; Prostate/metabolism*; Prostatic Hyperplasia/chemically induced; Rats, Sprague-Dawley; Up-Regulation/drug effects